Bristol-Myers Squibb succession
Confirmation of Wayne Davidson as the top pharmaceutical officer in the combined businesses has rekindled interest in the post-Gelb management. Chairman Richard Gelb has set June 1993 as the target for his retirement. At that date, current Vice Chairman William Miller will be 64. Likely replacement will come from current triumverate of exec VPs: Davidson, Charles Heimbold and Michael Autera. Heimbold, 56, has responsibility for consumer products, the health care group (medical devices) and planning and development. Autera is chief financial officer and head of administration, a key post in a major merger period.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.